Protocol Ledger

NCT06455059 · Phase III · ACTIVE NOT RECRUITING

Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia

Interventional Phase III clinical trial protocol NCT06455059 sponsored by BioMarin Pharmaceutical in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-17 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06455059
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06455059
Protocol FieldVerified Registry Value
NCT IdentifierNCT06455059
Consolidated Lead SponsorBioMarin Pharmaceutical
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2024-06-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI